Dr Hsieh Wen-Son

BS Neuroscience (Tulane), MD (Johns Hopkins), Internal Medicine (Duke), Medical Oncology (Johns Hopkins), Diplomate Internal Medicine and Medical Oncology ABIM (USA).


“I’m in oncology because it offers the opportunity to help patients in so many different ways.”

Dr Wen-son Hsieh is specialised in the treatment of various types of cancers and is active in developing novel cancer diagnostics and molecularly targeted anti-cancer treatments. After studying Philosophy and Psychology at Oxford University on a prestigious Rhodes Scholarship, Dr Hsieh completed his medical training at Johns Hopkins University and Duke University. After completion of his training in Internal Medicine and Medical Oncology, Dr Hsieh was active in patient care, teaching, and research as a full time faculty member at the Johns Hopkins University School of Medicine with a primary appointment in the division of haematologic malignancies. He remains a part time Assistant Professor at Johns Hopkins University and is a Principal Associate at the Cancer Sciences Institute of Singapore at the National University of Singapore, where he is active in the development of novel tests to diagnose cancer and novel treatments for cancer.

With a research interest in molecularly targeted cancer therapies, immunotherapy and molecular diagnostics, Dr Hsieh has led a number of international studies involving centres in Singapore, Hong Kong, Korea, the Philippines, Myanmar and the United States examining novel treatments and novel diagnostic tests for nasopharyngeal and hepatocellular carcinoma. He is also currently the principal investigator of more than ten active clinical trials investigating novel treatments for a variety of cancers. Dr Hsieh has authored over 80 scientific articles, abstracts, and book chapters and has lectured extensively at regional and international medical and scientific conferences. Dr Hsieh is committed to providing state of art, evidence-based treatment for current cancer patients as well as to developing more effective cancer treatments with less side effects for the future

Sub specialty interests include haematological malignancies including lymphomas, head and neck cancers and hepatobiliary cancers.